People die every day waiting for new treatments .
E-mails released Thursday show John Jenkins , director of the Office of New Drugs , on Aug. 13 said Graham 's findings include `` pretty strong language . ''
The company was already facing two class action lawsuits alleging patient harm from Vioxx .
But Northwestern University rheumatologist Thomas Schnitzer argued for ditching Vioxx entirely because Merck 's scientists could not explain why the drug started causing heart attacks after 18 months .
FitzGerald also challenged Pfizer 's contention that no science shows increased risk from Celebrex .
